Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

Sherief Abd-Elsalam50 enrolled

Overview

The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

The primary aim of the study is to evaluate the anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colon Cancer Stage

Interventions

FOLFERIDRUG

FOLFERI regimen

Folferi and celecoxibDRUG

Folferi regimen and celecoxib

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * advanced colorectal cancer Exclusion Criteria: * cerebral metastases * other malignancy * H pylori infection * thromboembolism

Locations (1)

Amira Roushdy

Tanta, Elgharbia, Egypt

RECRUITING

Outcomes

Primary Outcomes

number of patients with improved radiology

Time frame: 6 months

Central Contacts

Sherief Abd-Elsalam, MD

CONTACT

00201147773440 sheriefabdelsalam@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.